In this episode, ConcertAI CEO Jeff Elton sits down with Mike Rossi, PhD - ConcertAI's Clinical Genomics Lead - to explore how real-world genomic and clinical data are transforming early-stage oncology research. From the evolution of next-generation sequencing to liquid biopsy innovations, they unpack how integrated data sources are helping biopharma optimize study design, reduce trial risk, and accelerate breakthroughs. With insights into AI-powered simulations, patient journey mapping, and the strategic shift toward real-time decision-making, this conversation is essential listening for anyone in translational medicine or clinical development. 

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

In this episode of The ConcertAI Podcast, Jeff Elton, CEO of ConcertAI, engages with Ariel Berger, Executive Director of Integrated Solutions of Evidera, part of the PPD™ clinical research business of Thermo Fisher Scientific, to explore the innovative uses of real-world data (RWD) in regulatory settings, particularly in oncology. They discuss the critical role of RWD in shaping clinical trials and supporting regulatory decisions, emphasizing its growing importance in the regulatory approval process. The conversation also delves into the complexities of integrating AI and advanced data technologies to enhance trial designs and outcomes, highlighting how these tools are revolutionizing drug development efficiency and precision in patient care. Through insightful dialogue, the episode illuminates the transformative impact of these technologies on the future of healthcare and precision medicine.

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

In the season three opener of The ConcertAI Podcast, our guest Rory Kelleher (Senior Director, Global Head of Business Development, Life Sciences) from NVIDIA delves into the transformative role of AI in healthcare and life sciences. With a rich background at NVIDIA, Rory shares insights into NVIDIA’s journey from a GPU manufacturer to a leader in AI computation. This episode explores NVIDIA’s initiatives like the Clara platform, which seamlessly integrates AI into medical imaging and genomics, significantly accelerating drug discovery and patient care processes. Rory and host, Jeff Elton, discuss the collaborative dynamics between ConcertAI and NVIDIA, focusing on innovative AI-driven models designed to revolutionize clinical trial design and execution. The future looks promising with the potential development of reasoning models and multimodal patient foundation models, poised to deliver personalized healthcare solutions more effectively. Tune in to discover how NVIDIA's technology is paving the way for advancements in life sciences.

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

In this compelling episode of The ConcertAI Podcast, host Jeff Elton sits down with ABC's senior national correspondent, Steve Osunsami, to discuss the critical importance of prostate cancer screening and awareness. Steve shares his personal journey with prostate cancer, from initial diagnosis at age 41 to treatment and recovery. He highlights the significance of early detection, particularly for high-risk groups such as African American men, and the life-saving potential of regular PSA testing. Through his candid storytelling, Steve addresses the the challenges men face regarding prostate cancer, including the stigma around sexual function, and advocates for increased awareness and proactive health measures. This episode is a powerful reminder of the importance of self-advocacy and the need for tailored healthcare guidelines to better serve diverse populations. 

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

September marks Prostate Cancer Awareness Month, and to honor this, our latest episode of the ConcertAI Podcast features a special session with top urological cancer specialists. Host Jeff Elton welcomes Jennifer Rider and Kathryn Penney to our studio in Harvard Square, Cambridge, MA. Both guests are distinguished cancer epidemiologists who bring a wealth of knowledge and experience in prostate cancer research. 

In this episode, you will hear about the personal journeys of our guests into the field of cancer research, the significant advancements they have contributed to, and the vital role of genetic studies in improving patient care. The discussion delves into the importance of the Gleason scoring system for determining patient prognosis and explores the integration of AI and digital pathology to enhance diagnosis and treatment strategies. This conversation is essential for anyone interested in the latest in prostate cancer research and the evolving treatment strategies that could redefine patient outcomes.

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

Jeff Elton sits down with Dr. Robert Miller, Chief Medical and Science Officer at CancerLinQ, to unpack the integration of real-world data and AI in oncology care. Dr. Miller shares his journey from community practice to shaping CancerLinQ, revealing insights into the network's growth and its pivotal role in improving patient care. The episode delves into the transformation of quality measures, the burgeoning role of electronic health records, and the automation of data to enhance the quality and reach of oncological care. As CancerLinQ evolves, discover its expanding capabilities, the drive towards patient-centric care, and the influence on CancerLinQ's partnerships, particularly with ASCO. This is a must-listen for professionals seeking to understand the landscape of data-driven healthcare improvements. Tune in to explore the trajectory of oncology practice transformation with two industry leaders at the helm.

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

Jeff Elton, CEO of ConcertAI, and George Sledge, CMO of Caris Life Sciences, embark on an insightful journey through the advancements in oncology. They explore the transformative power of molecular diagnostic testing and how comprehensive data sets are revolutionizing personalized medicine. Delving into topics like the rise of liquid biopsies, which enable non-invasive, next-gen sequencing, they highlight the potential for easier and safer tumor monitoring. Challenges like the limitations of analyzing small populations are addressed, emphasizing the value of large-scale, actionable databases in understanding diseases like breast cancer. They also discuss the future of molecular diagnostics in streamlining cancer prevention trials and the need to look beyond "gateway mutations" for a deeper understanding of dynamic cancer evolution. A key theme is the collaborative synergy between ConcertAI and Caris Life Sciences, emphasizing the goal of producing high-quality, meaningful data that can shape the future of oncological research and care.

Interested in learning more about ConcertAI and Caris Life Science's joint offering? Download our factsheet today!

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

In this engaging episode, David Spetzler, President of Caris Life Sciences, and Jeff Elton, CEO of ConcertAI, discuss the transformative power of combining clinical insights and advanced AI technologies to revolutionize patient care in oncology. Highlighting their collaborative efforts, they emphasize the critical role of comprehensive data analysis, from leveraging longitudinal clinical records to employing next-generation sequencing for personalized treatment strategies. The conversation underscores a shared commitment to advancing medical science by accelerating the development and validation of new therapies, ultimately aiming to enhance patient outcomes through precision medicine. Through this partnership, they envision a future where diagnostics and targeted treatment strategies significantly extend human life years, demonstrating the profound impact of integrating cutting-edge technology and collaborative innovation in healthcare.

Watch the live video interview here:
https://vimeo.com/816357933/ab745bd0a1?share=copy

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

The second episode of The ConcertAI Podcast features Dr. Sibel Blau and Caroline Merillat, key figures in the Quality Cancer Care Alliance (QCCA) and creators of Exigent. This initiative aims to improve clinical research in community oncology, making trials more accessible and reflective of standard care populations. Dr. Blau, motivated by a dream to cure cancer, emphasized the importance of maintaining the independence of oncology practices for superior patient care. Merillat, with extensive experience in research, is dedicated to expanding trial access, especially for underserved populations. Exigent, by leveraging real-world data and collaborative efforts, seeks to enhance trial quality and speed, emphasizing a patient-centric approach that prioritizes the right trials for patients. This innovative model showcases the potential of community oncology to lead in research and patient care, underscoring the significance of independent practices in the healthcare ecosystem.

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

In this captivating episode of The ConcertAI Podcast, we dive deep with Jennifer Rider, a renowned cancer epidemiologist. Jennifer shares her journey from academia to the dynamic world of real-world data (RWD) and its vital role in oncology research. We explore how RWD is transforming the landscape of prostate cancer studies and its increasing importance in regulatory decision-making.

Discover how the field of RWD has evolved and its pivotal contributions to the development and application of groundbreaking oncology treatments. Jennifer's insights into the integration of RWD in clinical trials and its potential to shape future cancer therapies are truly enlightening.

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai